Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered app could help diabetics predict blood sugar and dose insulin smarter

NCT ID NCT07304778

Disease control Sponsor: Universidad Complutense de Madrid Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a mobile app called glUCModel that uses artificial intelligence to predict glucose levels and help people with type 1 diabetes decide how much insulin to take. About 34 adults aged 18 to 65 will use the app for several weeks while wearing a continuous glucose monitor. The main goal is to see if the app helps them keep their blood sugar in a healthy range more often and reduces dangerous highs and lows.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
glUCModel mobile app (AI-powered decision support system)
What this could lead to
If it works, this could give people with type 1 diabetes a smarter tool to manage their insulin doses and reduce dangerous blood sugar swings.
What could go wrong
This is a small early trial with only 34 people, so results may not apply to everyone. The app is a support tool, not a cure, and its benefits may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 34 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * HbA1c \< 9% * Currently following an MDI Bolus-Basal therapy. * Wearing CGMs connected to a mobile phone. * Spanish language proficiency. * Willingness to participate in the trial. * At least one year since the time of diabetes diagnosis. * Ability to use a mobile application like glUCModel. * Own a mobile phone running Android or iOS operating system. * Ability to follow a Portion-controlled diet for diabetes. * Educated to do an active management of insulin dosing Exclusion Criteria: * HbA1c \< 9%. * Not wearing CGMs. * Non-Spanish language proficiency. * Less than one year since the time of diabetes diagnosis * Unable to use a mobile application like glUCModel * Unable to follow a Portion-controlled diet for diabetes * Unable to do an active management of insulin dosing. * Diagnosed with a significant psychiatric disorder. * Subjects in treatment with corticoids * Patients who have required hospitalization or surgery in the last six months. * Pregnancy or planning a pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes (insulin-requiring, type 1 or type 2) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes (insulin-requiring, type 1 or type 2)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Universitario de Toledo

    RECRUITING

    Toledo, Toledo, 45007, Spain

  • Universidad Complutense de Madrid

    NOT_YET_RECRUITING

    Madrid, Madrid, 280240, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.